At $1,226, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on:

While its cardiometabolic drugs portfolio continues to anchor near-term growth, the company is quietly executing a major pivot. Through acquisitions like AtaiBeckley and Curevo, it is building entirely new platforms. These moves target complex areas like treatment-resistant depression and infectious disease prevention, expanding the company’s long-term therapeutic reach.

This expansion is…